Assessment of dabigatran plasma concentration may improve the safety of anticoagulation in patients treated with ibrutinib with concomitant atrial fibrillation

No abstract is available for this paper.

• Publication year

  2020

• Venue

  Unknown venue

• Publication date

  Unknown publication date

• Fields of study

  Not labeled

• Identifiers

  No identifiers available.

• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar

• No claims are published for this paper.

• No concepts are published for this paper.

• Bleeding in anticoagulated patients with atrial fibrillation: practical considerations.

  2020cited by this paper
• Ibrutinib-Associated Atrial Fibrillation.

  2018cited by this paper
• Dabigatran in ibrutinib‐treated patients with atrial fibrillation and lymphoproliferative diseases: Experience of 4 cases

  2018cited by this paper
• How and when to measure anticoagulant effects of direct oral anticoagulants? Practical issues.

  2018cited by this paper
• Atrial fibrillation as a complication of ibrutinib therapy: clinical features and challenges of management

  2018cited by this paper
• Practical management of ibrutinib in the real life: Focus on atrial fibrillation and bleeding

  2018cited by this paper
• Cumulative incidence, risk factors, and management of atrial fibrillation in patients receiving ibrutinib.

  2017cited by this paper
• Ibrutinib‐associated bleeding: pathogenesis, management and risk reduction strategies

  2017cited by this paper
• Practical recommendations for the choice of anticoagulants in the management of patients with atrial fibrillation on ibrutinib

  2017cited by this paper
• Increased dabigatran plasma concentration during Ibrutinib treatment: a case of cerebral hemorrhage and successful dabigatran reversal by idarucizumab

  2017cited by this paper
• Effect of standardized perioperative dabigatran interruption on the residual anticoagulation effect at the time of surgery or procedure

  2016cited by this paper
• Ibrutinib as Initial Therapy for Patients with Chronic Lymphocytic Leukemia.

  2015cited by this paper
• Dabigatran etexilate for stroke prevention in patients with atrial fibrillation: Resolving uncertainties in routine practice

  2012cited by this paper

• No citing papers are available for this paper.